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Human cell linesAbstract Based on the heterocyclic core of bendamustine, four series (4a–g, 5a–f, 8a–b and 9a–b)
of benzimidazole derivatives were designed and synthesized starting from 4-(1H-benzo[d]imidazol-
2-yl)-4-oxobutanehydrazide. In the rational design of target molecules, the benzimidazole ring of
bendamustine was retained and the bis-(chloroethyl) amine group (mechlorethamine) was substi-
tuted with several biologically active scaffolds such as oxadiazole, thiadiazole, and triazolo-
thiadiazines, in the hope of obtaining novel cytotoxic agents with improved efficacy and safety.
Cytotoxic activities of the designed analogues were carried out at the National Cancer Institute
(NCI), USA, against full NCI 60 human cell lines. Among all the tested compounds, 4fonance;
h; MG-
; DTP,
ood and
azines as
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a source of new anticancer agents. Arabian(761982/1) exhibited significant antiproliferative activity and was further screened at 10-fold dilu-
tions of five different concentrations (0.01, 0.1, 1, 10 and 100 lM) with GI50 values ranging from
0.09 to 16.2 lM and found superior for CNS cancer cell line SNB-75 (GI50 0.09, TGI 1.39, LC50
>100 and log10GI50 7.0, log10TGI-5.86, log10LC50 >4.00). Docking study was also performed
to provide an insight about the binding mode into binding sites of topoisomerase enzyme.
Hopefully in future, compound 4f could be used as a lead compound for developing new anticancer
agents.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is a disease in which uncharacteristic cells grow and
proliferate in an uncontrolled manner. It can occur in all the
living cells at any stage of life. Cancer is a major health
problem across the globe and its prevalence is on the rise.
Millions of people worldwide are suffering from this dreaded
disease which not only affects the health of the patient, but
also puts significant socioeconomic, mental and physical
burden on the family members (Lee et al., 2002; Kidwai
et al., 2002). Cancer is considered to be one of the leading
causes of mortality due to diseases and the projected death
toll due to cancer alone would touch approximately 10 mil-
lion by the end of year 2020 (Schumacher et al., 2011). In
spite of considerable development in the understanding of
molecular mechanisms of pathogenesis of the disease, yet
no specific treatment is available to cure the disease com-
pletely. The current approaches used to treat cancer involve
surgery, radiotherapy and chemotherapy either alone or in
combination, but due to metastasis i.e. invasion of nearby
tissues by cancerous cells and spreading of disease to other
parts of the body, can cure only 40% patients and thus
associated with the high rate of mortality. The other
approaches such as hormonal, antibodies treatments, biolog-
ical response modifier, and complementary and alternative
medicine treatments are also practiced worldwide to curb
this group of different and distinct diseases. Chemotherapy
is considered to be the main weapon against the neoplastic
diseases and the majority of the clinically used anticancer
molecules are of synthetic origin. These chemopreventive
molecules act by various molecular mechanisms which may
involve inhibition of initiation, promotion, progression and
metastasis of cancerous cells but in the process can also kill
normal cells leading to toxicity. There is an urgent need to
design and synthesize potent and highly selective molecules
to improve the current anticancer therapy with least or no
toxicity to normal cells.
Benzimidazole (a phenyl ring fused to an imidazole ring)
is a well known bioactive heterocyclic ring system that is
present in several natural and synthetic medicinal com-
pounds. Benzimidazole is known to be a versatile scaffold
that possess potential anticancer, antitumor and antiprolif-
erative activities (Refaat, 2010; Gumus et al., 2009; Sun
et al., 2011; Abonia et al., 2011; Ramla et al., 2006;
Demirayak et al., 2002; Romero-Castro et al., 2011) along
with other useful biological actions. Similarly, oxadiazole,
thiadiazole, triazolo-thiadiazines and triazolo-thiadiazoles
are a course group of heterocyclic compounds, which have
engrossed significant attention of medicinal chemists owinget al., Design and synthesis of benzimid
Journal of Chemistry (2015), http://dx.dto their wide range of useful pharmacological actions par-
ticularly cytotoxic activities against DNA topoisomerase I
(Formagio et al., 2008; Kumar et al., 2010; Sarhan et al.,
2010).
Bendamustine hydrochloride, a potent DNA alkylating
agent, is used clinically to treat chronic lymphocytic leukemia
(CLL) and B-cell non-hodgkin’s lymphoma (NHL)
(Lissitchkov et al., 2006; Gandhi and Burger, 2009). The cen-
tral core of Bendamustine is a benzimidazole heterocyclic ring
having a mechlorethamine side chain on the 5th position, a
butyric acid substituent on a 2nd position and N-substituted
methyl group on 1st position. Thus, chemically bendamustine
is; (1H-benzimidazole-2-butanoicacid-5-[bis(2-chloroethyl)ami
no]-1-methylmonohydro chloride) and was developed as a
rational design of purine analogue and alkylation hybrid of
chlorambucil (Fig. 1). In view of these facts, we intended to
synthesize some novel and potent anticancer agents based on
the rationally designed template of bendamustine and chlo-
rambucil i.e. molecules having benzimidazole residue as a
pharmacophoric group (Romero-Castro et al., 2011) with
butyric acid substituent and further clubbed with related hete-
rocyclic rings such as oxadiazole, thiadiazole, triazolo-
thiadiazole and triazolo-thiadiazine (Fig. 1). The designed tem-
plate was further used to synthesize library of analogue mole-
cules (Schemes 1–3) by incorporating heterocyclic ring systems
of several antitumor agents reported in the literature such as
proxazole (Duanmu et al., 1989), IMC-094332 (Britten et al.,
2001) (having oxadiazole ring, 4a–g), SNS-032 (Penning
et al., 2008) (having thiazole ring, 5a–f), levamisole (Tolner
et al., 2001) and ATEK 10934 (Albert et al., 2007) (having dia-
zole–thiazole & triazolo-thiadiazole ring; 8a–b & 9a–b)
(Fig. 2). Chemical structures of some other reported antitumor
agents containing benzimidazole nucleus and other biologi-
cally active monocyclic or bicyclic heterocyclic ring system
along with the similarly prepared molecules (4f, 5e and 9a)
are presented in Chart 1. Molecules such as, Nocodazole
(NSC-238189) (1) (Duanmu et al., 1989), FB642 (2) (Britten
et al., 2001), A-620223 (3) (Penning et al., 2008), Hoechst-
33258 (4) (Tolner et al., 2001), ABT-888 (5) (Albert et al.,
2007), Phortress (6) (Bradshaw and Westwell, 2004), SNS-
032 (7) (Misra et al., 2004), Proxazole (8) (Dalip et al.,
2011), CYC116 (9) (Griffiths et al., 2008), thiadiazole deriva-
tive (10) (Matysiak and Opolski, 2006), Levamisole (11)
(Remrs et al., 1982), imidazo[2,1-b][1,3,4] thiadiazole ana-
logues (12) (Taher et al., 2012), triazolo [1,3,4] thiadiazole
derivative (13) (Ibrahim, 2009), ATEK 10934 (14) (Ibrahim,
2009), and IMC-094332 (15) (Maria et al., 2010) have shown
potential to be used as antitumor agents and some of them
are in the final stages of drug development.azoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Figure 1 Rationally designed template for targeted molecules obtained from the marketed anticancer drugs such as bendamustine and
chlormabucil.
Bendamustine analogues as new anticancer agents 3Our previous and ongoing research work on the synthesis
of benzimidazole derivatives bearing different heterocyclic
rings in search of new anticancer agents have revealed that
these compounds are selective toward Leukemia cancer sub-
panel with mean GI50 6.59, GI50 12.62 and GI50 1.04
(Rashid et al., 2012a,b; Husain et al., 2012, 2013). From these
results, we have observed that substituted benzimidazoles
have the potential to provide the anticancer lead candidate
or a drug molecule and thus are worthy of further studies.
The study was undertaken with an aim to find new structures
which could be used as a lead candidate in the field of cancer.
We report herein the synthesis of some new molecules in
which benzimidazole core of bendamustine drug is endowed
with oxadiazole, triazolo-thiadiazine and triazolo-thiadiazole
nuclei, in an attempt to significantly improve the anticancer
activity of the marketed anticancer drug. The in-vitro anti-
cancer activities of newly designed and synthesized com-
pounds were carried out at the National Cancer InstitutePlease cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.d(NCI), Chemotherapeutic Research division, USA. The cyto-
toxic effects of the compounds were tested on nine human
systems against full NCI 60 cell line panel. The tested com-
pounds were also granted NCS code by NCI and are shown
in Table 1.2. Experimental
2.1. General information
The melting points of the all the synthesized compounds
were measured on a liquid paraffin bath in open capillary
tubes and are uncorrected. The progress of the chemical
reaction as well as the purity of the target compounds was
checked by using TLC plates, pre-coated with silica gel G
in solvent systems of toluene: ethyl acetate: formic acid
(5:4:1, v/v/v) and benzene: acetone (9:1, v/v). The spots onzoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Scheme 1 The route for synthetic protocol of title compounds (4a–g).
Scheme 2 The route for synthetic protocol of title compounds (5a–g).
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Scheme 3 The route for synthetic protocol of title compounds (8a–b and 9a–b).
Bendamustine analogues as new anticancer agents 5TLC plates were visualized after exposing to iodine vapors
or under UV-light. Chemical synthesis was carried out in
a scientific microwave synthesizer (model No. CATA-R,
Catalyst systems, India). Flash chromatography technique
was used to purify the target compounds using hexane
and ethyl acetate mixture as an eluent mixture. 1H- and
13C-Nuclear magnetic resonance (NMR) spectra of the pure
compounds in DMSO-d6/CDCl3 were recorded on Bruker
spectrospin DPX-300 MHz instrument. Tetramethylsilane
was used as an internal reference and the exchangeable pro-
tons of OH and NH were confirmed by the D2O shaking
test. Mass spectra were recorded on LCMS/MS (Perkin–
Elmer and LABINDIA, Applied Biosystem) model no.
API 3000 and is presented as m/z. IR spectra of the com-
pounds were recorded on FT/IR (Jasco, Japan), model no.
410. An elemental analysis was done on a Perkin–Elmer
240 analyzer and was found in the range of ±0.5% for each
element analyzed (C, H and N).
2.2. Synthesis
2.2.1. 4-(1H-benzo[d]imidazol-2-yl)-4-oxobutanoicacid (1)
It was prepared as per the previously reported method
(Husain et al., 2012). The identity of the compound was
established after comparing its physical properties and spectral
data which are found to be in good agreement with the
reported literature values.Please cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.d2.2.2. Ethyl-4-(1H-benzo[d]imidazol-2-yl)-4-oxobutanoate (2)
It was prepared as per the previously reported method (Husain
et al., 2012). The identity of the compound was established
after comparing its physical properties and mass spectral data
with the literature values.
2.2.3. 4-(1H-benzo[d]imidazol-2-yl)-4-oxobutanehydrazide (3)
It was prepared as per the previously reported method (Husain
et al., 2012). The identity of the compound was established
after comparing its physical properties and spectral data which
are found to be in good agreement with the reported literature
values.
2.2.4. 1-(1H-benzo[d]imidazol-2-yl)-3-(5-(chloromethyl)-
1,3,4-oxadiazol-2-yl) propan-1-one (4)
An equimolar mixture of 4-(1H-benzo[d]imidazol-2-yl)-4-oxo
butanehydrazide (3; 0.001 mol) and a chloroacetic acid
(0.001 mol) in POCl3 (5 mL)was placed in amicrowave reaction
compatible glass vessel having amagnetic stirrer bar for mixing.
The reaction mixture was irradiated at a power level of 6 (60%,
420 W) for 13 min in a scientific microwave synthesizer. The
reaction mixture was cooled, poured slowly onto the crushed
ice and finally neutralized with sodium bicarbonate solution to
produce the solid precipitates. The mixture was filtered, washed
with plenty of water and dried. Yield: 78%, mp 223–224 C,
Rf = 0.61. IR (KBr, cm
1): 3348(NAH), 3020(ACAH,ArAH),
2936(ACAH, CH2), 1709(C‚O), 1684(AC‚N), 1573(C‚C),zoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Figure 2 Rationale template for the different synthetic schemes.
6 M. Rashid et al.1305(ANAN‚C), 1166(CAOAC, asymmetric), 1027
(CAOAC, symmetric), 712(CACl). 1H NMR (CDCl3): 12.50
(s, 1H, NH, D2O exchangeable), 7.79(d, 1H, J= 7.8 Hz, H-4,
benzimidazole ring), 7.47(t, 1H, J= 7.2 Hz, H-7, benzimida-
zole), 7.35(t, 2H, J= 5.4 Hz, H-5,6, benzimidazole), 4.39(s,
2H, ACH2Cl), 3.29(t, 2H, J= 6.9 Hz, CH2), 2.90(t, 2H,
J= 6.6 Hz, ACH2C‚O).
13C NMR (CDCl3): 168.45(C‚O),
158.23, 156.37(C, oxadiazole), 154.69(C‚N), 136.14, 132.24,
132.15, 126.55, 126.12, 124.83(ArAC), 51.02(CH2Cl), 39.76
(CH2, CH2CO), 28.51(CH2). ESI-MS (m/z): 290(M
+). Anal.
calcd. for C13H11ClN4O2: C, 53.71; H, 3.81; N, 19.27. Found:
C, 53.74; H, 3.90; N, 19.30. Eluent mixture ratio (9:1).
2.2.5. General procedure for the synthesis of 1-(1H-benzo[d]
imidazol-2-yl)-3-(5-(methyl substituted)-1,3,4-oxadiazol-2-yl)
propan-1-one (4a–g)
An equimolar amount compound 4 (0.003 mol) and a sec-
ondary amine (0.003 mol) were suspended in absolute ethanol
(10 mL). The suspension was added to a magnetic stir bar
equipped microwave reaction vessel and just before microwave
irradiation, sodium acetate (0.001 mol) was added. The micro-
wave was operated at a power level of 5 (50%, 350 W) for 8–
14 min. The content of the reaction mixture was cooled,Please cite this article in press as: Rashid, M. et al., Design and synthesis of benzimid
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dpoured onto crushed ice and acidified with glacial acetic acid
to obtain a solid mass. The solid product was filtered, repeat-
edly washed with water to flush the inorganic components and
finally dried.
2.2.5.1. 3-(5-((6-amino-9H-purin-9-yl)methyl)-1,3,4-oxadia-
zol-2-yl)-1-(1H-benzo[d]imidazol-2-yl)propan-1-one (4a).
Yield: 90%, mp 225–226 C, Rf = 0.67. IR (KBr, cm1):
3352(NAH), 3027(CAH, ArAH), 2987(CAH, CH2), 1716
(C‚O), 1682(C‚N), 1568(C‚C), 1312(NAN‚C), 1160
(CAOAC, asymmetric), 1022(CAOAC, symmetric), 834
(CAN).1H NMR (CDCl3): 12.63(s, 1H, NH,D2O exchange-
able, benzimidazole), 8.51(s, 2H, NH2,D2O exchangeable,
adenine), 8.37(s, 1H, adenine), 7.97(s, 1H, adenine), 7.70(d,
1H, J= 7.5 Hz, H-4, benzimidazole), 7.49(t, 1H,
J= 7.8 Hz, H-7, benzimidazole), 7.27(t, 2H, J= 7.5 Hz, H-
5,6, benzimidazole), 4.17(s, 2H, CH2, adenine), 2.96(t, 2H,
J= 7.2 Hz, CH2), 2.51(t, 2H, J= 7.2 Hz, CH2CO).
13C
NMR (CDCl3): 175.31(C‚O), 161.74, 160.12(C, oxadiazole),
153.17(C‚N), 141.32, 138.61, 137.52, 136.79, 134.92, 129.81,
129.03, 128.56, 127.63, 124.74, 122.87(ArAC), 63.41(CH2,
adenine), 30.72(CH2, CH2CO), 28.45(CH2). ESI-MS (m/z):
389(M+). Anal. calcd. for C18H15N9O2: C, 55.52; H, 3.87;azoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Chart 1 Reported structure (1–15) of some biologically active anticancer containing benzimidazole, oxadiazole, hiadiazole and
triazolothidiazole scaffold, and rationale designing target compounds (4f, 5e & 9b) having above hybrid nuclei.
Bendamustine analogues as new anticancer agents 7N, 32.38. Found: C, 55.86; H, 3.96; N, 32.47. Eluent mixture
ratio (8:2).
2.2.5.2. 1-((5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-
1,3,4-oxadiazol-2-yl)methyl)-1H-purin-6(9H)-one (4b). Yield:
87%, mp 233–234 C, Rf = 0.65. IR (KBr, cm1): 3364
(NAH), 3086(CAH, ArAH), 2952(CAH, CH2), 1724(C‚O),
1672(C‚N), 1480(C‚C), 1328(NAN‚C), 1116(CAOAC,
asymmetric), 1020(CAOAC, symmetric). 1H NMR (CDCl3):
12.31(s, 1H, NH, D2O exchangeable, benzimidazole), 10.87(s,Please cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dH, NH, D2O exchangeable, guanine), 8.02(s, 1H, guanine),
7.85(s, 1H, guanine), 7.78(d, 1H, J= 7.8 Hz, H-4, benzimida-
zole), 7.40(t, 1H, J= 7.8 Hz, H-7, benzimidazole), 7.27(t, 2H,
J= 7.5 Hz, H-5,6, benzimidazole), 3.92(s, 2H, CH2, guanine),
3.23(t, 2H, J= 6.9 Hz, CH2), 2.85(t, 2H, J= 7.2 Hz,
CH2CO).
13C NMR (CDCl3): 168.73(C‚O), 166. 23(C‚O,
guanine), 158.45, 157.31(C, oxadiazole), 156.85(C‚N),
137.93, 137.12, 136.87, 134.92, 127.53, 126.74, 124.56, 124.01,
122.87, 120.91(ArAC), 57.37(CH2, guanine), 38.61(CH2,
CH2CO), 25.43(CH2). ESI-MS (m/z): 390(M
+). Anal. calcd.zoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Table 1 NSC: Code, sensitivity, growth percent, mean growth percent of NCI cancer cell lines treated with synthesized compounds
(10 lM) and activity.
Compd. NSC: code The most sensitive cell line Growth % of the most
sensitive cell lineb
Range of growth, % Mean Activitya
3 758071/1 UO-31 (Renal Cancer) 86.64 86.64–134.77 102.34 Inactive
4 755135/1 MALME-3M (Melanoma) 82.96 82.96–121.44 102.35 Inactive
4a 755140/1 UO-31 (Renal Cancer) 84.84 84.84–129.33 106.04 Inactive
4b 755141/1 CCRF-CEM (Leukemia) 28.46 28.46–125.48 96.09 Active
4c 755142/1 SR (Leukemia) 82.01 82.01–126.78 105.73 Inactive
4d Ntc – – – – –
4e 755143/1 MALME-3M (Melanoma) 77.82 77.82–123.77 104.78 Inactive
4f 761982/1 MDA-MB-435 (Melanoma) 45.79 45.79–90.70 20.03 Active
4g 761983/1 MOLT-4 (Leukemia) 8.54 8.54–104.24 78.75 Active
5a Ntc – – – – –
5b Ntc – – – – –
5c Ntc – – – – –
5d 755144/1 UO-31 (Renal Cancer) 85.04 85.04–121.47 102.43 Inactive
5e 755145/1 CCRF-CEM (Leukemia) 68.09 68.09–116.72 94.39 Active
5f 755146/1 UO-31 (Renal Cancer) 85.11 85.11–124.27 107.30 Inactive
6 759213/1 HL-60(TB) (Leukemia) 72.55 72.55–128.74 104.14 Inactive
7 Ntc – – – – –
8a 760467/1 UO-31 (Renal Cancer) 72.63 72.63–126.41 97.18 Inactive
8b 761989/1 K-562 (Leukemia) 3.14 3.14–129.13 93.97 Active
9a 761988/1 K-562 (Leukemia) 5.84 5.84–116.27 92.86 Active
9b Ntc – – – – –
a The compound which showed growth inhibition 6 32%, active for that particular cell line.
b Percent cell growth reduction following 48 h incubation with test compounds (used sulforhodamine B procedure).
c Not selected by NCI for anticancer screening.
8 M. Rashid et al.for C18H14N8O3: C, 55.38; H, 3.60; N, 28.71. Found: C, 55.41;
H, 3.74; N, 28.92. Eluent mixture ratio (8:2).
2.2.5.3. 3-(5-((1H-1,2,4-triazol-1-yl)methyl)-1,3,4-oxadiazol-
2-yl)-1-(1H-benzo[d]imidazol-2-yl) propan-1-one (4c). Yield:
92%, mp 221–222 C, Rf= 0.56. IR (KBr, cm1): 3321(NAH),
3178(CAH, ArAH), 2819(CAH, CH2), 1724(C‚O), 1662
(C‚N), 1523(C‚C), 1384(NAN‚C), 1191(CAOAC, asymmet-
ric), 1033(CAOAC, symmetric), 848(CAN). 1H NMR (CDCl3):
12.03(s, 1H, NH, D2O exchangeable), 8.04(s, 1H, H-5, triazole),
7.88(s, 1H,H-3, triazole), 7.79(d, 1H, J= 8.1 Hz,H-4, benzimida-
zole), 7.63(t, 1H, J= 7.2 Hz, H-7, benzimidazole), 7.45(t, 2H,
J= 7.2 Hz, H-5,6, benzimidazole), 4.73(s, 2H, CH2, triazole),
3.29(t, 2H, J= 6.9 Hz, CH2), 2.87(t, 2H, J= 6.9 Hz, CH2CO).
13CNMR (CDCl3): 172.87(C‚O), 165.11, 161.19(C, oxadiazole),
155.05(C‚N), 132.83, 131.96, 129.86, 128.52, 124.73, 123.48,
117.67, 115.68(ArAC), 60.24(C, triazole), 30.23(CH2, CH2CO),
28.20(CH2). ESI-MS (m/z): 323(M
+). Anal. calcd. for
C15H13N7O2: C, 55.72; H, 4.05; N, 30.33. Found: C, 55.75; H,
4.13; N, 30.39. Eluent mixture ratio (7:3).
2.2.5.4. 3-(5-((4H-1,2,4-triazol-4-ylamino)methyl)-1,3,4-oxa-
diazol-2-yl)-1-(1H-benzo[d]imidazol-2-yl) propan-1-one (4d).
Yield: 85%, mp 215–217 C, Rf = 0.53. IR (KBr, cm1):
3319(NAH), 3104(CAH, ArAH), 2994(CH2), 1698(C‚O),
1612(C‚N), 1574(C‚C), 1356(NAN‚C), 1178(CAOAC,
asymmetric), 1036(CAOAC, symmetric), 834(CAN). 1H
NMR (CDCl3): 12.47(s, 1H, NH, D2O exchangeable), 7.89(s,
2H, triazole), 7.61(d, 1H, J= 7.8 Hz, H-4, benzimidazole),
7.33(t, 1H, J= 7.5 Hz, H-7, benzimidazole), 7.26(t, 2H,
J= 7.8 Hz, H-5,6, benzimidazole), 3.72(s, 2H, CH2, CH2NH),
3.21(t, 2H, J= 6.9 Hz, CH2), 2.92(t, 2H, J= 6.9 Hz,Please cite this article in press as: Rashid, M. et al., Design and synthesis of benzimid
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dCH2CO), 2.63(s, IH, NH).
13C NMR (CDCl3): 176.10
(C‚O), 163.41, 160.85(C, oxadiazole), 155.71(C‚N), 137.32
(C, aminotriazole), 129.63, 128.91, 124.73, 123.86, 121.18,
120.83(ArAC), 66.51(CH2, NHCH2), 32.68(CH2, CH2CO),
28.38(CH2). ESI-MS (m/z): 338(M
+). Anal. calcd. for
C15H14N8O2: C, 53.25; H, 4.17; N, 33.12. Found: C, 53.43;
H, 4.25; N, 33.71. Eluent mixture ratio (7:3).
2.2.5.5. 3-(5-((1H-imidazol-1-yl)methyl)-1,3,4-oxadiazol-2-
yl)-1-(1H-benzo[d]imidazol-2-yl) propan-1-one (4e). Yield:
82%, mp 207–208 C, Rf = 0.57. IR (KBr, cm1): 3348
(NAH), 3054(CAH, ArAH), 2942(CAH, CH2), 1726(C‚O),
1685(C‚N), 1532(C‚C), 1328(NAN‚C), 1176(CAOAC,
asymmetric), 1042(CAOAC, symmetric). 1H NMR (CDCl3):
11.87(s, 1H, NH, D2O exchangeable), 8.07(s, 1H, H-2, imida-
zole), 7.74(d, 1H, J= 7.5 Hz, H-4, benzimidazole), 7.30(t, 1H,
J= 7.5 Hz, H-7, benzimidazole), 7.27(t, 2H, J= 7.5 Hz, H-
5,6, benzimidazole), 6.65(d, 1H, J= 7.2 Hz, H-5, imidazole),
6.48(d, 1H, J= 8.1 Hz, H-4, imidazole), 4.03(s, 2H, CH2, imi-
dazole), 3.12(t, 2H, J= 7.2 Hz, CH2), 2.85(t, 2H, J= 6.9 Hz,
CH2CO).
13C NMR (CDCl3): 175.21(C‚O), 161.92, 158.32(C,
oxadiazole), 154.63(C‚N), 136.25, 132.53, 131.54(C, imida-
zole), 126.43, 125.82, 123.35, 122.61, 121.57, 119.64(ArAC),
60.73(CH2, imidazole), 35.31(CH2, CH2CO), 27.93(CH2).
ESI-MS (m/z): 322(M+). Anal. calcd. for C16H14N6O2: C,
59.612; H, 4.37; N, 26.06. Found: C, 59.74; H, 4.25; N,
26.35. Eluent mixture ratio (8:2).
2.2.5.6. 3-((5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-1,
3,4-oxadiazol-2-yl)methyl)-5-methyl pyrimiidine-2,4 (1H, 3H)-
dione (4f). Yield: 85%, mp236 C, Rf = 0.58. IR (KBr, cm1):
3344(NAH), 3105(CAH, ArAH), 29774(CAH, CH2),azoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Bendamustine analogues as new anticancer agents 91724(C‚O), 1662(C‚N), 1566(C‚C), 1384(NAN‚C), 1180
(CAOAC, asymmetric), 1064(CAOAC, symmetric). 1H NMR
(CDCl3): 14.10(s, 1H, NH, D2O exchangeable, pyrimidine),
12.37(s, 1H, NH, D2O exchangeable, benzimidazole), 8.03(s,
1H, pyrimidine), 7.68(d, 1H, J= 7.7 Hz, H-4, benzimidazole),
7.43(t, 1H, J= 7.2 Hz, H-7, benzimidazole), 7.29(dd, 2H,
J= 7.8 Hz, J= 7.5 Hz, H-5,6, benzimidazole), 4.09(s, 2H,
CH2, pyrimidine), 3.49(t, 2H, J= 6.9 Hz, CH2), 3.09(t, 2H,
J= 7.0 Hz, CH2, CH2CO), 2.57(s, 3H, CH3).
13C NMR
(CDCl3): 173.61(C‚O), 173.14, 172.15(C‚O, pyrimidine),
159.29, 159.13(C, oxadiazole), 156.41(C‚N), 132.54, 130.94,
129.78, 129.84, 128.87, 128.48, 124.16, 115.70(ArAC), 60.55
(CH2, pyrimidine), 30.40(CH2, CH2CO), 28.05(CH2), 14.31
(CH3). ESI-MS (m/z): 380(M
+). Anal. calcd. for
C18H16N6O4: C, 56.84; H, 4.24; N, 22.10. Found: C, 56.87;
H, 4.33; N, 22.17. Eluent mixture ratio (9:1).
2.2.5.7. 1-((5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-1,
3,4-oxadiazol-2-yl)methyl)-4-amino pyrimidin-2(1H)-one
(4g). Yield: 82%, mp 234–235 C, Rf = 0.59. IR (KBr,
cm1): 3372(NAH), 3043(CAH, ArAH), 2957(CAH, CH2),
1703(C‚O), 1674(C‚N), 1587(C‚C), 1372(NAN‚C),
1184(CAOAC, asymmetric), 1065(CAOAC, symmetric). 1H
NMR (CDCl3): 12.17(s, 1H, NH, D2O exchangeable), 8.34
(d, 1H, J= 8.1 Hz, pyrimidine), 8.01(s, 2H, NH2,D2O
exchangeable), 7.71(d, 1H, J= 7.5 Hz, H-4, benzimidazole),
7.33(t, 1H, J= 7.2 Hz, H-7, benzimidazole), 7.24(t, 2H,
J= 8.1 Hz, H-5,6, benzimidazole), 6.72(d, 1H, J= 7.5 Hz,
pyrimidine), 4.13(s, 2H, CH2, pyrimidine), 3.28(t, 2H, J=
7.2 Hz, CH2), 2.76(t, 2H, J= 6.9 Hz, CH2CO).
13C NMR
(CDCl3): 174.53(C‚O), 165.01(CO, pyrimidine), 160.23,
159.10(C, oxadiazole), 155.41(C‚N), 138.10, 135.29, 130.13,
129.69, 128.43, 123.14, 120.34, 118.72, 110.51(ArAC), 55.72
(CH2, pyrimidine), 32.56(CH2, CH2CO), 27.13(CH2). ESI-
MS (m/z): 365(M+). Anal. calcd. for C17H15N7O3: C, 55.89;
H, 4.14; N, 26.84. Found: C, 55.97; H, 3.64; N, 26.95. Eluent
mixture ratio (8:2).
2.2.6. 1-(1H-benzo[d]imidazol-2-yl)-3-(5-mercapto-1,3,4-
thiadiazol-2-yl)propan-1-one (5)
The compound 3 (0.015 mol) and potassium hydroxide
(0.020 mol) were dissolved in ethylalcohol (40 mL) to form a
solution. Afterward, carbon disulfide (0.020 mol) was slowly
introduced into the reaction mixture with constant stirring
and left at room temperature for 10 h. After that the ice cold
conc. H2SO4 (5 mL) was gradually added in small increments
over a period of 10 min and the resulting mixture was further
stirred for 4 h at room temperature. It was then poured over
crushed ice to obtain the solid precipitate which was recrystal-
lized with carbinol.
Yield: 74%; Mp. 223–225 C; Rf = 0.43(T:E:F). IR (KBr,
cm1): 3343(NAH), 3058(CAH, ArAH), 2931(CAH, CH2),
2589(SAH), 1694(C‚O), 1651(C‚N), 1607(C‚C), 1380
(NAN‚C), 1067(CASAC). 1H NMR (DMSO-d6): d 13.23(s,
1H, SH, D2O exchangeable), 11.37(s, 1H, NH, D2O exchange-
able), 7.85(d, 1H, J= 7.5 Hz, H-4, benzimidazole), 7.51(t, 1H,
J= 6.9 Hz, H-7, benzimidazole), 7.30(t, 2H, J= 7.5 Hz, H-
5,6, benzimidazole), 3.34(t, 2H, J= 6.9 Hz, CH2), 2.84(t,
2H, J= 6.9 Hz, CH2, CH2CO).
13C NMR (DMSO-d6):
d 175.11(C‚O), 161.73, 155.61(2C, thiadiazole), 157.72Please cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.d(C‚N), 133.87, 132.65, 130.61, 129.41, 124.72, 116.81(ArAC),
32.45(CH2, CH2CO), 21.75(CH2). ESI-MS (m/z): 290(M
+).
Anal. calcd. for C12H10N4OS2: C, 49.64; H, 3.48; N, 19.30.
Found: C, 49.61; H, 3.51; N, 19.47.
2.2.7. General procedure for the synthesis of 1-(1H-benzo[d]
imidazol-2-yl)-3-(5-mercapto substituted-1,3,4-thiadiazol-2-yl)
propan-1-one (5a–f)
A solution of compound 5 (0.001 mol) and an aryl or alkyl
chloride compound (0.001 mol) in ethanolic alkali solvent
(0.08 g KOH in 15 mL ethanol) was placed in the scientific
microwave synthesizer and irradiated at power level of 5
(50%, 350 W) for 10–14 min, The reaction mixture was decom-
posed by adding on to the crushed ice which on usual workup
yielded the solid dried products (5a–f).
2.2.7.1. 5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-1,3,4-
thiadiazol-2-yl-2-chloroethanethioate (5a). Yield: 85%, mp
239 C, Rf = 0.45. IR (KBr, cm1): 3398(NAH), 3097(CAH,
ArAH), 2896(CH2), 1724(C‚O), 1612(C‚N), 1504(C‚C),
1384(NAN‚C), 1060(CASAC), 837(CACl), 759(CAS). 1H
NMR (CDCl3): 11.75(s, 1H, NH, D2O exchangeable), 7.81
(d, 1H, J= 8.7 Hz, H-4, benzimidazole), 7.49(t, 1H,
J= 7.8 Hz, H-7, benzimidazole), 7.35(t, 2H, J= 7.8 Hz, H-
5,6, benzimidazole), 3.72(s, 2H, CH2Cl), 3.32(t, 2H,
J= 7.2 Hz, CH2), 2.92(t, 2H, J= 6.9 Hz, CH2CO).
13C
NMR (DMSO-d6): 175.57(C‚O), 168.76(C‚O, COCH2Cl),
162.24, 159.67(C, thiadiazole), 154.96(C‚N), 132.21, 131.84,
130.19, 128.57, 124.65, 123.64(ArAC), 34.25(CH2, CH2Cl),
31.37(CH2, CH2CO), 29.32(CH2). ESI-MS (m/z): 366(M
+).
Anal. calcd. for C14H11ClN4O2S2: C, 45.84; H, 3.03; N,
15.27. Found: C, 45.87; H, 3.08; N, 15.41. Eluent mixture ratio
(8:2).
2.2.7.2. 2-(5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-
1,3,4-thiadiazol-2-ylthio)acetic acid (5b). Yield: 84%, mp
245–247 C, Rf = 0.43. IR (KBr, cm1): 3371(OAH), 3299
(NAH), 3060(CAH, ArAH), 2968(CAH, CH2), 1722(C‚O),
1650(C‚N), 1516(C‚C), 1365(NAN‚C), 1064(CASAC),
718(CAS). 1H NMR (CDCl3): 12.62(s, 1H, NH, D2O
exchangeable), 10.44(s, 1H, OH, D2O exchangeable), 7.59(d,
1H, J= 7.5 Hz, H-4, benzimidazole), 7.23(t, 1H, J= 7.8 Hz,
H-7, benzimidazole), 7.19(t, 2H, J= 7.5 Hz, H-5,6, benzimi-
dazole), 4.15(s, 2H, CH2COOH), 2.95(t, 2H, J= 7.2 Hz,
CH2), 2.58(t, 2H, J= 6.9 Hz, CH2CO).
13C NMR (CDCl3):
173.45(C‚O), 170.83(C‚O, COOH), 163.27, 162.35(C, thia-
diazole), 154.21(C‚N), 131.74, 129.51, 124.63, 123.45,
122.05, 121.67(ArAC), 37.51(CH2, CH2COOH), 33.84(CH2,
CH2CO), 28.30(CH2). ESI-MS (m/z): 348(M
+). Anal. calcd.
for C14H12N4O3S2: C, 48.26; H, 3.47; N, 16.08. Found: C,
48.37; H, 4.05; N, 16.75. Eluent mixture ratio (9:1).
2.2.7.3. 1-(1H-benzo[d]imidazol-2-yl)-3-(5-(2-bromoethylth-
io)-1,3,4-thiadiazol-2-yl)propan-1-one (5c). Yield: 92%, mp
237–238 C, Rf = 0.52. IR (KBr, cm1): 3375(NAH), 3043
(CAH, ArAH), 2952(CAH, CH2), 1720(C‚O), 1643(C‚N),
1502(C‚C), 1312(NAN‚C), 1082(CASAC), 720(CAS), 664
(CABr). 1H NMR (CDCl3): 12.10(s, 1H, NH, D2O exchange-
able), 7.71(d, 1H, J= 7.8 Hz, H-4, benzimidazole), 7.41(t, 1H,
J= 7.5 Hz, H-7, benzimidazole), 7.29(t, 2H, J= 7.8 Hz,zoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
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2H, J= 6.9 Hz, CH2S), 3.23(t, 2H, J= 7.2 Hz, CH2), 2.87(t,
2H, J= 7.2 Hz, CH2CO).
13C NMR (CDCl3): 174.61
(C‚O), 162.74, 160.53(C, thiadiazole), 153.82(C‚N),
132.54, 130.12, 128.32, 124.57, 123.42, 122.81(ArAC), 45.23,
40.35(CH2CH2Br), 31.92(CH2, CH2CO), 27.73(CH2). ESI-
MS (m/z): 397(M+). Anal. calcd. for C14H13BrN4OS2: C,
42.32; H, 3.30; N, 14.10. Found: C, 41.86; H, 3.51; N, 14.23.
Eluent mixture ratio (8:2).
2.2.7.4. 5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-1,3,
4-thiadiazol-2-yl-benzothioate (5d). Yield: 80%, mp 235 C,
Rf = 0.56. IR (KBr, cm
1): 3367(NAH), 3058(CAH, ArAH),
2977(CAH, CH2), 1677(C‚O), 1600(C‚N), 1504(C‚C),
1384(NAN‚C), 1045(CASAC), 752(CAS). 1H NMR
(CDCl3): 12.37(s, 1H, NH, D2O exchangeable), 8.14(d, 1H,
J= 7.5 Hz, H-4, benzimidazole), 7.79(t, 1H, J= 8.1 Hz, H-
7, benzimidazole), 7.61(t, 2H, J= 7.2 Hz, H-5,6, benzimida-
zole), 7.50–7.26(m, 5H, phenyl), 3.29(t, 2H, J= 6.9 Hz,
CH2), 2.90(t, 2H, J= 6.9 Hz, CH2CO).
13C NMR (CDCl3):
175.85(C‚O), 175.31(C‚O, phenyl), 162.32, 160.72(C, thia-
diazole), 154.67(C‚N), 133.54, 132.27, 132.05, 131.97,
131.34, 130.72, 129.32, 128.73, 124.58, 123.21, 121.67, 120.67
(ArAC), 32.81(CH2, CH2CO), 27.94(CH2). ESI-MS (m/z):
394(M+). Anal. calcd. for C19H14N4O2S2: C, 57.85; H, 3.59;
N, 14.20. Found: C, 57.91; H, 3.52; N, 14.35. Eluent mixture
ratio (8:2).
2.2.7.5. 1-(1H-benzo[d]imidazol-2-yl)-3-(5-(benzylthio)-1,3,
4-thiadiazol-2-yl)propan-1-one (5e). Yield: 78%, mp 223–
224 C, Rf = 0.66. IR (KBr, cm1): 3362(NAH), 3053(CAH,
ArAH), 2947(CAH, CH2), 1697(C‚O), 1664(C‚N), 1582
(C‚C), 1368(NAN‚C), 1052(CASAC), 724(CAS). 1H
NMR (CDCl3): 12.47(s, 1H, NH, D2O exchangeable), 7.87
(d, 1H, J= 7.8 Hz, H-4, benzimidazole), 7.77(t, 1H,
J= 8.1 Hz, H-7, benzimidazole), 7.60(t, 2H, J= 7.8 Hz,
H-5,6, benzimidazole), 7.53–6.96(m, 5H, phenyl), 3.87(s, 2H,
CH2S), 3.42(t, 2H, J= 7.2 Hz, CH2), 2.88(t, 2H, J= 7.2 Hz,
CH2CO).
13C NMR (CDCl3): 173.15(C‚O), 163.87, 162.10
(C, thiadiazole), 156.30(C‚N), 132.91, 132.14, 131.48,
130.17, 129.65, 128.71, 125.80, 124.01, 123.27, 123.12, 118.54,
117.93(ArAC), 41.35(CH2, CH2S), 31.53(CH2, CH2CO),
27.43(CH2). ESI-MS (m/z): 380(M
+). Anal. calcd. for C19H16-
N4OS2: C, 59.98; H, 4.24; N, 14.73. Found: C, 60.3; H, 4.51;
N, 14.85. Eluent mixture ratio (6:4).
2.2.7.6. 2-(5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-1,3,
4-thiadiazol-2-ylthio)acetamide (5f). Yield: 76%, mp 225–
226 C, Rf = 0.54. IR (KBr, cm1): 3381(NAH), 3053(CAH,
ArAH), 2932(CAH, CH2), 1727(C‚O), 1652(C‚N), 1527
(C‚C), 1373(NAN‚C), 1047(CASAC), 720(CAS). 1H
NMR (CDCl3): 12.51(s, 1H, NH, D2O exchangeable), 8.31(s,
2H, NH2, D2O exchangeable), 7.90(d, 1H, J= 7.5 Hz, H-4,
benzimidazole), 7.65(t, 1H, J= 7.2 Hz, H-7, benzimidazole),
7.39(t, 2H, J= 7.8 Hz, H-5,6, benzimidazole), 3.97(s, 2H,
CH2CONH2), 3.19(t, 2H, J= 6.9 Hz, CH2), 2.85(t, 2H,
J= 7.2 Hz, CH2CO).
13C NMR (CDCl3): 173.21(C‚O),
171.34(C‚O, CONH2), 161.51, 158.72(C-thiadiazole), 155.63
(C‚N), 130.42, 129.51, 128.53, 124.16, 123.93, 123.25(ArAC),
58.17(CH2, CH2CONH2), 31.02(CH2, CH2CO), 25.31(CH2).
ESI-MS (m/z): 347(M+). Anal. calcd. for C14H13N5O2S2: C,Please cite this article in press as: Rashid, M. et al., Design and synthesis of benzimid
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.d48.40; H, 3.77; N, 20.16. Found: C, 48.47; H, 3.75; N, 20.41.
Eluent mixture ratio (7:3).
2.2.8. 1-(1H-benzo[d]imidazol-2-yl)-3-(5-mercapto-1,3,4-
oxadiazol-2-yl)propan-1-one (6)
It was prepared as per the previously reported method (Husain
et al., 2013). The identity of the compound was established
after comparing its physical properties and spectral data which
are found to be in good agreement with the reported literature
values.
2.2.9. 3-(4-amino-5-mercapto-4H-1,2,4-triazol-3-yl)-1-(1H-
benzo[d]imidazol-2-yl)propan-1-one (7)
It was prepared as per the previously reported method (Husain
et al., 2013). The identity of the compound was established
after comparing its physical properties and spectral data which
are found to be in good agreement with the reported literature
values.
2.2.10. General procedure for synthesis of 1-(1H-benzo[d]
imidazol-2-yl)-3-(6-substituted-7H-[1,2,4] triazolo[3,4-b]
[1,3,4]thiadiazin-3-yl)propan-1-one (8a–b)
An equimolar solution of compound 7 (0.003 mol) and a-
chloro containing methyl compound (0.003 mol) was prepared
in absolute ethanol (15 mL). The solution after refluxing for 3–
4 h was cooled to room temperature and then neutralized with
ammonia solution to yield a solid product.
2.2.10.1. 1-(1H-benzo[d]imidazol-2-yl)-3-(6-phenyl-7H-[1,2,
4]triazolo[3,4-b][1,3,4]thiadiazin-3-yl) propan-1-one (8a).
Yield: 65%, mp 240–241 C, Rf = 0.67. IR (KBr, cm1): 3354
(NAH), 3027(CAH, ArAH), 2968(CAH, CH2), 1694(C‚O),
1612(C‚N), 1575(C‚C), 1363(N‚CAS), 1258(NAN‚C).
1H NMR (CDCl3): 12.31(s, 1H, NH, D2O exchangeable),
8.10–7.86(m, 5H, AC6H5), 7.78(d, 1H, J= 7.8 Hz, H-4, benz-
imidazole), 7.48(t, 1H, J= 7.5 Hz, H-7, benzimidazole), 7.30
(t, 2H, J= 7.5 Hz,H-5,6, benzimidazole), 3.73(s, 2H, CH2, cyc-
lic), 3.35(t, 2H, J= 7.2 Hz, CH2), 2.93(t, 2H, J= 6.9 Hz, CH2,
CH2CO).
13C NMR (CDCl3): 170.42(C‚O), 161.54, 160.72(C,
triazole), 156.20, 154.86(C‚N), 135.38, 132.19, 131.94, 129.52,
129.12, 128.23, 127.43, 126.75, 125.73, 117.24, 116.71, 115.76
(ArAC), 51.75(CH2, cyclic), 29.96(CH2, CH2CO), 27.97(CH2).
ESI-MS (m/z): 388(M+). Anal. calcd. for C20H16N6OS: C,
61.84;H, 4.15; N, 21.63. Found: C, 61.95;H, 4.37;N, 21.69. Elu-
ent mixture ratio (6:4).
2.2.10.2. 1-(1H-benzo[d]imidazol-2-yl)-3-(6-(4-methoxyphe-
nyl)-7H-[1,2,4]triazolo[3,4-b] [1,3,4] thiadiazin-3-yl) pro-
pan-1-one (8b). Yield: 60%, mp 231–232 C, Rf = 0.62. IR
(KBr, cm1): 3361(NAH), 3037(CAH, ArAH), 2965(CAH,
CH2), 1703(C‚O), 1652(C‚N), 1582(C‚C), 1374(N‚CAS),
1237(NAN‚C). 1H NMR (CDCl3): 12.03(s, 1H, NH, D2O
exchangeable), 7.99–7.69(m, 4H, phenyl), 7.45(d, 1H,
J= 8.1 Hz, H-4, benzimidazole), 7.32(t, 1H, J= 7.8 Hz, H-
7, benzimidazole), 7.24(t, 2H, J= 7.5 Hz, H-5,6, benzimida-
zole), 4.11(s, 2H, CH2, cyclic), 3.52(s, 3H, OCH3), 3.24(t,
2H, J= 6.9 Hz, CH2), 2.86(t, 2H, J= 6.9 Hz, CH2CO).
13C
NMR (CDCl3): 176.26(C‚O), 159.04, 158.83(C, triazole),
156.20, 154.75(C‚N), 133.29, 132.05, 129.69, 128.43, 123.14,
122.13, 121.63, 120.72, 117.38, 116.81, 115.97, 115.78(ArAC),azoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
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(CH2). ESI-MS (m/z): 418(M
+). Anal. calcd. for C21H18N6O2-
S: C, 60.27; H, 4.34; N, 20.08. Found: C, 61.54; H, 4.73; N,
20.35. Eluent mixture ratio (7:3).
2.2.11. General procedure for synthesis of 1-(1H-benzo[d]
imidazol-2-yl)-3-(6-(substituted)-[1,2,4] triazolo[3,4-b] [1, 3,
4]thiadiazol-3-yl)propan-1-one (9a–b)
An equimolar solution of compound 7 (0.003 mol) and a-
chloro containing carbonyl compounds (0.003 mol) was pre-
pared in absolute ethanol (15 mL). The solution after refluxing
for 3–4 h was cooled to room temperature and then neutralized
with ammonia solution to yield a solid product.
2.2.11.1. 1-(1H-benzo[d]imidazol-2-yl)-3-(6-phenyl-[1,2,4]-
triazolo[3,4-b][1,3,4]thiadiazol-3-yl)propan-1-one (9a).
Yield: 61%, mp 220–22 C, Rf = 0.62. IR (KBr, cm1): 3398
(NAH), 3016(CAH, ArAH), 2904(CAH, CH2), 1728(C‚O),
1665(C‚N), 1616(C‚C), 1384(N‚CAS), 1265(NAN‚C).
1H NMR (CDCl3): 11.01(s, 1H, NH, D2O exchangeable),
7.83(d, 1H, J= 8.4 Hz, H-4, benzimidazole), 7.73(t, 1H,
J= 8.1 Hz, H-7, benzimidazole), 7.65(t, 2H, J= 7.2 Hz, H-
5,6, benzimidazole), 7.51–7.34(m, 5H, phenyl), 3.01(t, 2H,
J= 8.1 Hz, CH2), 2.51(t, 2H, J= 8.1 Hz, CH2, CH2CO).
13C NMR (CDCl3): 170.37(C‚O), 159.25, 156.25(C, triazole),
153.97(C‚N), 148.68(C, thiadiazole), 132.51, 130.48, 129.51,
128.40, 128.01, 127.47, 126.95, 125.89, 123.58, 122.31, 117.38,
116.81(ArAC), 30.65(CH2, CH2CO), 28.03(CH2). ESI-MS
(m/z): 374(M+). Anal. calcd. for C19H14N6OS: C, 60.95; H,
3.77; N, 22.45. Found: C, 61.07; H, 3.80; N, 22.55. Eluent mix-
ture ratio (6:4).
2.2.11.2. 1-(1H-benzo[d]imidazol-2-yl)-3-(6-(4-hydroxyphen-
yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)propan-1-one
(9b). Yield: 68%, mp 231–232 C, Rf = 0.59. IR (KBr, cm1):
3371(NAH), 3061(CAH, ArAH), 2951(CAH, CH2), 1695
(C‚O), 1627(C‚N), 1587(C‚C), 1345(N‚CAS), 1250
(NAN‚C). 1H NMR (CDCl3): 11.97(s, 1H, NH, D2O
exchangeable), 7.75(d, 1H, J= 7.8 Hz, H-4, benzimidazole),
7.43(t, 1H, J= 7.8 Hz, H-7, benzimidazole), 7.34(t, 2H,
J= 7.5 Hz, H-5,6, benzimidazole), 7.27–7.03(m, 4H, phenyl),
6.15(s, 1H, OH), 3.27(t, 2H, J= 7.2 Hz, CH2), 2.95(t, 2H,
J= 6.9 Hz, CH2CO).
13C NMR (CDCl3): 169.27(C‚O),
158.33, 157.51(C, triazole), 154.15(C‚N), 144.23(C, thiadia-
zole), 130.82, 128.63, 128.35, 127.47, 126.95, 125.89, 123.58,
122.28, 122.16, 117.38, 116.81, 115.97(ArAC), 34.82(CH2,
CH2CO), 28.25(CH2). ESI-MS (m/z): 390(M
+). Anal. calcd.
for C19H14N6O2S: C, 58.48; H, 3.62; N, 21.523. Found: C,
58.48; H, 3.86; N, 21.74. Eluent mixture ratio (7:3).
2.3. In vitro anticancer methodology
The medium RPMI 1640 having a 5% fetal bovine serum and
2 mM L-glutamine was used to grow the human tumor cell
lines. The Microtiter plates were inoculated with the cancer
cells followed by incubation at ideal conditions for growth,
such as 37 C temperature, 5% CO2, 95% air and 100% rela-
tive humidity for a period of 24 h before treatment with the
tested compounds. After the incubation for 24 h, cell popula-
tion of each cell line at the time of sample addition (Tz) was
measured by fixing two plates of each cell line with TCAPlease cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.din situ. The sample was dissolved in DMSO at 400-fold of
the desired final maximum test concentration and stored in
frozen conditions until its further use in experiments. An ali-
quot of frozen concentrate of test sample was shaken to liquefy
the content at the time of sample addition to cell lines and
diluted to twofold with the complete medium containing
50 lg/mL gentamicin of the desired final maximum concentra-
tion. In addition to this, another four, 10-fold or ø log serial
dilutions were prepared to have five different concentrations
and a control. The different dilutions of sample in aliquots
of 100 lL were added to the appropriate Microtiter wells hav-
ing 100 lL of medium to obtain the desired final sample con-
centrations. After the addition of sample, the plates were again
incubated for an additional 48 h at the standard temperature,
air and humidity conditions. An accurately measured 50 lL of
cold 50% (w/v) TCA (final concentration, 10% TCA) was
gently added to fix the cells in situ and incubated at 4 C for
a duration of 60 min. The supernatant was rejected and the
plates were thoroughly washed five times with tap water and
finally dried in air. A 4% (w/v) solution of Sulforhodamine
B (SRB) (100 lL) prepared in 1% acetic acid was added to
each Microtiter well and the plates were incubated at room
temperature for another 10 min. A 10 mM Trizma base was
subsequently added to solubilize the bound stain and the
absorption of resulting mixture was recorded at 515 nm using
an automated micro plate reader (Grever et al., 1992; Monks
et al., 1991). A total of seven absorbance (optical density) read-
ings were recorded at [time zero, (Tz), control growth (C) and
test growth in the presence of sample at five concentration
levels (Ti)]. The Percentage Growth (PG) i.e. the effect of the
compound on growth of a cell line was calculated as by using
the following formula:
If ðMean OD testMean ODtzeroÞ > 0: then
PG ¼ 100 ðMean ODtest-Mean ODtzeroÞ
=ðMean ODcrtlMean ODtzeroÞ
If ðMean ODtestMean ODtzeroÞ < 0: then
PG ¼ 100 ðMean ODtestMean ODtzeroÞ=Mean ODtzero
where Mean ODtzero represents an average of optical density
(OD) measurements of SRB-derived color just before exposure
of cells to the screened sample. Mean ODtest is the average of
optical OD measurements of SRB-derived color after 48 h
exposure of cells to the screened sample. Mean ODctrl stands
for an average of OD measurements of SRB-derived color
after 48 h with no exposure of cells to the test compound. Each
concentration was expressed as the log10 (molar or lg/mL) and
the response parameters values of GI50, TGI and LC50 were
interpolated which indicate the concentrations at which the
PG is +50, 0 and 50 respectively.
The IC50 value has been renamed by NCI into special con-
centration parameters (GI50, TGI and LC50). Percentage
growth inhibition was calculated as follows:
½ðTiTzÞ=ðCTzÞ  100 for concentrations for which
Ti > = ¼ Tz
½ðTiTzÞ=Tz  100 for concentrations for which Ti < Tz
Three dose response parameters viz. GI50, TGI and LC50
were calculated for each cell line subpanel. GI50 or Growth
inhibition of 50% was deduced from [(Ti  Tz)/(C  Tz)] 
100 = 50 (It is the drug concentration which results in azoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
12 M. Rashid et al.50% decrease in the net protein increase). Total growth inhibi-
tion (TGI) was calculated from the Ti = Tz (i.e. a concentra-
tion at which the total growth inhibition is 100%) while LC50
was calculated from [(Ti  Tz)/Tz]  100 = 50 (concentra-
tion of the drug which results in a 50% reduction in the mea-
sured protein at the end of the drug exposure as compared to
that in the beginning) indicating a net loss of the cells (Holbeck
et al., 2010; Boyd and Paull, 1995). The dose response curve is
plotted to get a fair idea about the growth percentage
inhibition of cell lines at a particular concentration of the
tested sample. The points at which the curve crosses the
horizontal grid lines correspond to parameters; GI50 (crosses
at +50 line), TGI (crosses at 0 line) and LC50 (crosses at
50 line), respectively.
2.4. Molecular docking studies
The molecular docking studies were performed with the help of
a Maestro 9.0 docking software (Schrodinger Inc. USA) on the
3D structure of DNA topoisomerase complex enzyme. A win-
dows 7 based 64 bit operating systems using an HCl computer
[Intel (R) Core (TM) i5-2400 CPU @ 3.10 GHz, 8 GB mem-
ory] was used to carry out the docking studies. The 3D struc-
ture of DNA topoisomerase enzyme for the study was
downloaded from the Protein Data Bank (PDB ID: 1SC7).
It has 96% similarity with the human cell enzyme and all active
site residues in the vicinity of cofactor have exact counterparts.
The downloaded structure was further refined for idealFigure 3 The 3D, optimization and 3D, viewer with space fill mod
(Bendamustine). The different groups of structure showed with differen
nitrogen with red color, oxygen with lime color, sulfur with yellow co
Please cite this article in press as: Rashid, M. et al., Design and synthesis of benzimid
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.ddocking results (Staker et al., 2005). The PDB enzyme struc-
ture was thoroughly analyzed for missing atoms, bonds and/
or contacts. All the residues and water molecules except ligand
from the enzyme structure were removed manually. A builder
molecule was used to construct the ligand molecules and then
to obtain a stable structure, the energy of the molecule was
also minimized. With the help of a grid box, the active sites
were generated on the molecule. The conformation corre-
sponding to the lowest energy was selected and subjected to
an energy minimization.
3. Results and discussion
3.1. Chemistry
The target compounds were prepared as per the synthetic route
outlined in Schemes 1–3. The starting material 4-(1H-
benzo[d]imidazol-2-yl)-4-oxobutanoic acid (1) was synthesized
by oxidative cyclization of 1,2 diaminobenzene with a-
ketoglutaric acid in an acidified solution (4NHCl). The
compound (1) was converted to an ethyl ester (2) by simple
Fischer esterification reaction followed by treatment with
hydrazine hydrate to obtain 4-(1H-benzo[d]imidazol-2-yl)-
4-oxobutane hydrazide (3). The hydrazide (3) upon reaction
with chloroacetic acid in the presence of cyclizing agent,
(POCl3) under microwave irradiation yielded a compound
(4). The chloro group at the 5th position of the oxadiazole ring
of compound 1-(1H-benzo[d]imidazol-2-yl)-3-(5-(chloromeel of designed molecules 4f, 5e, 9b and marketed anticancer drug
t colors as such carbon with white color, hydrogen with cyan color,
lor and chlorine with magenta color.
azoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Table 2 NCI: DTP, The percentages of growth and inhibition of testing compound (4f, 761982/1) over the full panel of tumor cell
lines at a single dose (10 lM).
Panel Cell line name Developmental therapeutics program one dose mean graph value (10 lM)
Growth percent Growth inhibition percenta
Leukemia HL-60(TB) 0.43 100.43
K-562 10.38 89.62
MOLT-4 9.42 90.58
RPMI-8226 17.25 82.75
SR 4.57 95.43
Non-small cell lung cancer A549/ATCC 21.13 78.87
EKVX 54.89 45.11
HOP-62 17.72 82.28
HOP-92 53.21 46.79
NCI-H226 31.72 68.28
NCI-H23 36.88 63.12
NCI-H460 9.27 90.73
NCI-H522 12.71 87.29
Colon cancer COLO 205 32.71 132.71
HCC-2998 27.87 127.87
HCT-116 6.25 93.75
HCT-15 65.29 34.71
HT29 8.43 91.57
KM12 4.98 95.02
SW-620 28.93 71.07
CNS cancer SF-268 36.63 63.37
SF-295 21.47 78.53
SF-539 15.22 115.22
SNB-19 33.18 66.82
SNB-75 32.99 132.99
U251 16.65 83.35
Melanoma LOX IMVI 35.59 64.41
MALME-3M 47.85 52.15
M14 16.65 116.65
MDA-MB-435 45.79 145.79
SK-MEL-2 25.22 74.78
SK-MEL-28 40.86 59.14
SK-MEL-5 13.22 86.78
UACC-257 81.40 18.60
UACC-62 41.05 58.95
Ovarian cancer IGROV1 47.82 52.18
OVCAR-3 14.80 114.80
OVCAR-5 13.80 86.20
OVCAR-8 21.03 78.97
NCI/ADR-RES 90.70 9.30
SK-OV-3 7.95 107.95
Renal cancer 786-0 28.74 71.26
A498 11.54 88.46
ACHN 61.12 38.88
CAKI-1 63.47 36.53
RXF 393 7.83 107.83
SN12C 30.25 69.75
TK-10 64.11 35.89
UO-31 44.15 55.85
Prostate cancer PC-3 19.30 80.70
DU-145 35.32 135.32
Breast cancer MCF7 9.44 90.56
MDA-MB-231/ATCC 26.05 73.95
HS 578T 10.15 89.85
BT-549 18.86 81.14
T-47D 34.34 65.66
MDA-MB-468 1.54 101.54
Mean 20.03
a Percentage inhibition calculated by simple abstraction of % activity from 100 and % inhibition above 100 (100–200%) means that
compound shows lethality at cancer cells.
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Table 3 Calculated values of GI50, TGI, LC50 (in lM) of the NCI cell lines panel, MG-MID value and selectivity index of the
compound (4f, 761982/1).
Panel Cell line GI50 (lM) TGI (lM) LC50 (lM)
Concentration
per cell line
Subpanel
concentration
Subpanel
MIDb
Selectivity
index
Leukemia CCRF-CEM 0.459 4.932 0.82 2.55 >100 >100
HL-60(TB) 0.966 >100 >100
K-562 1.03 >100 >100
MOLT-4 1.69 >100 >100
RPMI-8226 0.340 >100 >100
SR 0.447 >100 >100
Non-small cell lung cancer A549/ATCC 0.542 22.248 2.47 0.85 >100 >100
EKVX 3.90 >100 >100
HOP-62 1.37 >100 >100
OP-92 1.44 >100 >100
NCI-H226 12.7 >100 >100
NCI-H23 0.627 >100 >100
NCI-H322M 0.904 >100 >100
NCI-H460 0.394 >100 >100
NCI-H522 0.371 2.86 >100
Colon cancer COLO 205 0.354 17.503 2.50 0.84 1.36 20.2
HCC-2998 0.459 4.88 >100
HCT-116 0.233 80.6 >100
HCT-15 15.2 >100 >100
HT29 0.237 >100 >100
KM12 0.415 10.9 >100
SW-620 0.605 >100 >100
CNS cancer SF-295 1.61 5.1791 1.03 2.03 36.2 >100
SF-539 0.799 29.9 >100
SNB-19 2.21 >100 >100
SNB-75 0.099 1.39 >100
U251 0.461 >100 >100
Melanoma LOX IMVI 0.543 6.97 0.77 2.71 >100 >100
MALME-3M 1.26 >100 >100
M14 0.386 2.80 >100
MDA-MB-435 0.174 0.393 ntc
SK-MEL-2 1.53 >100 >100
SK-MEL-28 0.829 >100 >100
SK-MEL-5 0.304 54.9 >100
UACC-257 1.29 >100 >100
UACC-62 0.654 >100 >100
Ovarian cancer IGROV1 0.914 20.637 2.95 0.71 >100 >100
OVCAR-3 0.353 1.82 >100
OVCAR-4 0.558 >100 >100
OVCAR-5 1.42 >100 >100
OVCAR-8 0.661 >100 >100
NCI/ADR-RES 16.2 49.7 >100
SK-OV-3 0.531 15.5 >100
Renal cancer 786-0 2.84 40.686 5.08 0.41 38.7 >100
A498 0.296 3.78 >100
ACHN 10.0 >100 >100
CAKI-1 11.5 >100 >100
RXF 393 2.11 6.77 >100
SN12C 2.51 >100 >100
TK-10 5.42 >100 >100
UO-31 6.01 >100 >100
Prostate cancer PC-3 0.725 1.149 0.57 3.66 >100 >100
DU-145 0.424 1.94 24.3
Breast cancer MCF7 0.216 4.502 0.75 2.78 >100 >100
MDA-MB- 0.902 >100 >100
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Table 3 (continued)
Panel Cell line GI50 (lM) TGI (lM) LC50 (lM)
Concentration
per cell line
Subpanel
concentration
Subpanel
MIDb
Selectivity
index
231/ATCC 0.413 5.41 >100
HS 578T 0.539 42.1 >100
BT-549 2.22 >100 >100
T-47D 0.212 ntc >100
MDA-MB-468
Total cell lines and total concentration 59 123.81
MIDa 2.09
a The average sensitivity of all cell lines toward the test agent in lM.
b The average sensitivity of all cell lines of a particular subpanel toward the test agent in lM.
c Not tested cell line.
Bendamustine analogues as new anticancer agents 15thyl)-1,3,4-oxadiazol-2-yl) propan-1-one (4) was further substi-
tuted with eight heterocyclic secondary amines. The reaction of
compound (4) with substituted secondary amines was carried
out in the presence of NaOAc by employing microwave radia-
tions to accomplish the synthesis of 1-(1H-benzo[d]imidazol-2-
yl)-3-(5-(methylsubstituted)-1,3,4-oxadiazol-2-yl)propan-1-ones
(4a–g) (Scheme 1). The compounds of the series (5a–f);
(1-(1H-benzo[d]imidazol-2-yl)-3-(5-mercaptosubstituted-1,3,4-
thiadiazol-2-yl) propan-1-one) were synthesized by reacting
compound 1-(1H-benzo[d]imidazol-2-yl)-3-(5-mercapto-1,3,4-
thiadiazol-2-yl)propan-1-one (5) with six different chloro
compounds (Scheme 2). Compound (3) was also cyclized with
CS2/KOH in ethanol to produce, 1-(1H-benzo[d]imidazol-2-y
l)-3-(5-mercapto-1,3,4-oxadiazol-2-yl) propan-1-one (6) which
on further treatment with hydrazine hydrate gave a compound
7, (3-(4-amino-5-mercapto-4H-1,2,4-triazol-3-yl)-1-(1H-benzo
[d]imidazol-2-yl)propan-1-one). Benzimidazole clubbed tria-
zolo compounds (7) were then condensed with two substituted
methyl chloride and two carbonyl chloride compounds to get
benzimidazole bearing substituted triazolo-thiadiazine and
triazolo-thiadiazole derivatives i.e. 1-(1H-benzo[d]imidazol-2-yl)
3-(6-substituted-7H-[1,2,4]triazolo[3,4-b] [1,3,4]thiadiazin-3-yl) pr
opan-1-one (8a–b) and 1-(1H-benzo[d]imidazol-2-yl)-3-(6-(substi
tuted)-[1,2,4]triazolo [3,4-b][1,3,4]thiadiazol-3-yl)propan-1-one
(9a–b), respectively (Scheme 3).
The structures of newly prepared compounds were eluci-
dated using modern, sophisticated analytical techniques viz.
FT-IR, 1H & 13C NMR and mass spectral data. The results
of C, H, N analysis were consistent with the proposed
structures and found within ±0.5% as compared with the the-
oretical values. In general, for all the synthesized compounds,
the absorption bands for carbonyl (C‚O) and secondary
amino (NAH) were observed in the range 1666–1728 and
3317–3429 cm1, respectively. The absorption peaks around
2599 and 1660 cm1 were accounted for S-H and C‚N. In
1H NMR spectra, the presence of a singlet around d 12.3 is
indicative of ring NAH and another singlet further downfield,
at d 13.4 is assigned to SAH, both these signals were
disappeared upon D2O shaking, which confirm the presence
of these groups in the synthesized molecules. The appearance
of peaks at d 173.1 and 154.9 in 13C NMR spectra could be
related to C‚O and C‚N. The distinct bands observed in
IR spectra nearly at 1384, 1060 and 1028 cm1 were accounted
for NAN‚C, CASAC and CAOAC which indicates thePlease cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dincorporation of oxadiazole and thiadiazole ring in the benz-
imidazole analogs. 1H NMR spectra of all the compounds
exhibited two triplets at appropriate position around d 2.8
(J= 6.9 Hz) and 3.2 (J= 7.2 Hz) and also in 13C NMR spec-
tra two signals were obtained around d 30.2 and 27.9, which
could be assigned to two methylene groups (ACH2ACH2A)
spacer, linker or bridge groups between the benzimidazole ring
and the other heterocyclic rings such as oxadiazole, thiadia-
zole, triazolo-thiadiazole, and triazolo-thiadiazine. The signals
for benzimidazole hydrogens in proton NMR appeared as
doublet, triplet at around d 7.6, 7.4 and 7.2 (7.8 Hz, 7.5 Hz,
7.5 Hz). The characteristic signals in 13C NMR spectra which
appeared at around d 161.1, 159.1 are related to oxadiazole
carbon ring and other signals at d 162.3, 160.7 are indicative
of the thiadiazole carbon ring. The 3D, optimization and
viewer of few designed molecules such as 4f, 5e, 9a and clini-
cally used anticancer drug, bendamustine have been shown
with space fill model (Fig. 3).
3.2. In vitro anticancer screening
A total of fifteen compounds were submitted to NCI for
in vitro anticancer screening against 60 human cell lines
obtained from nine clinically isolated cancer types and were
granted NCS-codes (Table 1). The prepared compounds were
tested at a single dose and added at a concentration
(1  105 M) followed by incubation of culture for the dura-
tion of 48 h. A protein binding dye ‘‘Sulforhodamine B” was
used for the end point determinations (Shoemaker, 2006;
Grever et al., 1992). The result of each tested compound on
the growth of cells is expressed in terms of percent growth of
treated cells in comparison with the untreated control cells.
Those compounds which diminished or inhibited the cell
line growth to 32% or less were regarded (a negative value is
suggestive of cell kills) as in vitro active (Table 1) (Corona
et al., 2009). Among all the tested compounds, 4b, 4f, 4g, 5e,
8b and 9a were observed to be active against CCRF-CEM (leu-
kemia), MDA-MB-435 (melanoma), MLT-4 (leukemia),
CCRF-CEM (leukemia) and K-562 (leukemia) cell lines
respectively. Except compound 4f, all other agents exhibited
low antiproliferative activity. The compound 4f (NSC:
761982/1) was the most active anticancer agent which met
the pre – determined criteria of growth inhibition and thus
was further chosen for the NCI full panel of five dose assayzoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Table 4 Values of the log molar concentration of response parameter (log10GI50, log10TGI and log10LC50) of the title compound (4f,
761982/1).
Cancer disease Used cell lines Potencya in lmol/L
Log10 GI50 Log10 TGI Log10 LC50
Leukemia CCRF-CEM 6.34 >4.00 >4.00
HL-60(TB) 6.01 >4.00 >4.00
K-562 5.99 >4.00 >4.00
MOLT-4 5.77 >4.00 >4.00
RPMI-8226 6.47 >4.00 >4.00
SR 6.35 >4.00 >4.00
Non-small cell lung cancer A549/ATCC 6.27 >4.00 >4.00
EKVX 5.41 >4.00 >4.00
HOP-62 5.86 >4.00 >4.00
OP-92 5.84 >4.00 >4.00
NCI-H226 4.89 >4.00 >4.00
NCI-H23 6.20 >4.00 >4.00
NCI-H322M 6.04 >4.00 >4.00
NCI-H460 6.40 >4.00 >4.00
NCI-H522 6.43 5.54 >4.00
Colon cancer COLO 205 6.45 5.87 4.69
HCC-2998 6.34 5.31 >4.00
HCT-116 6.63 4.09 >4.00
HCT-15 4.82 >4.00 >4.00
HT29 6.63 >4.00 >4.00
KM12 6.38 4.96 >4.00
SW-620 6.22 >4.00 >4.00
CNS cancer SF-295 5.79 4.44 >4.00
SF-539 6.10 4.53 >4.00
SNB-19 5.66 >4.00 >4.00
SNB-75 7.00 5.86 >4.00
U251 6.34 >4.00 >4.00
Melanoma LOX IMVI 6.26 >4.00 >4.00
MALME-3M 5.90 >4.00 >4.00
M14 6.41 5.55 >4.00
MDA-MB-435 6.76 6.41 ntb
SK-MEL-2 5.81 >4.00 >4.00
SK-MEL-28 6.08 >4.00 >4.00
SK-MEL-5 6.52 4.26 >4.00
UACC-257 5.89 >4.00 >4.00
UACC-62 6.18 >4.00 >4.00
Ovarian cancer IGROV1 6.04 >4.00 >4.00
OVCAR-3 6.45 5.74 >4.00
OVCAR-4 6.25 >4.00 >4.00
OVCAR-5 5.85 >4.00 >4.00
OVCAR-8 6.18 >4.00 >4.00
NCI/ADR-RES 4.79 4.30 >4.00
SK-OV-3 6.28 4.81 >4.00
Renal cancer 786-0 5.55 4.41 >4.00
A498 6.53 5.42 >4.00
ACHN 5.00 >4.00 >4.00
CAKI-1 4.94 >4.00 >4.00
RXF 393 5.68 5.17 >4.00
SN12C 5.60 >4.00 >4.00
TK-10 5.27 >4.00 >4.00
UO-31 5.22 >4.00 >4.00
Prostate cancer PC-3 6.14 >4.00 >4.00
DU-145 6.37 5.71 4.61
Breast cancer MCF7 6.67 >4.00 >4.00
MDA-MB-231/ATCC 6.04 >4.00 >4.00
HS 578T 6.38 5.27 >4.00
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Table 4 (continued)
Cancer disease Used cell lines Potencya in lmol/L
Log10 GI50 Log10 TGI Log10 LC50
BT-549 6.27 4.38 >4.00
T-47D 5.65 >4.00 >4.00
MDA-MB-468 6.67 ntb >4.00
MID 6.04 4.38 4.02
Delta 0.96 2.03 0.67
a Values determined using the optimal concentration range (s) for each end point.
b Not tested cell lines.
Bendamustine analogues as new anticancer agents 17method at 10-fold dilutions of five different concentrations
(0.01, 0.1, 1, 10 and 100 lM) (Table 2). Compound 4f showed
remarkable antiproliferative activity at all the five dosage levels
and therefore, further referred to Biological Evaluation Com-
mittee of NCI for advanced study (Monks et al., 1991).
The compound 4f (NSC: 761982/1) displayed remarkable
significant cytotoxic potential against all the investigated cell
lines which represent diverse sub-panels with GI50 values
obtained between 0.09 to 16.2 lM falling within the sensitive
range and exhibiting an outstanding antiproliferative activity
(Table 3). The compound was also found to be sensitive
against some individual cell lines and demonstrated the highest
activity against CNS cancer cell lines, such as SNB-75 (GI50
0.09, TGI 1.39, LC50 > 100 and log10GI50 7.0, log10TGI
5.86, log10LC50 >4.00). The analyzed date also indicated
an evident sensitivity profile against colon cancer subpanel
(GI50 value vary from 0.23 to 15.20 lM), least for HT29 and
highest for HCT-15 cell lines. The tested compound 4f was also
noted to be quite sensitive against other cell lines like in leuke-
mia, melanoma, CNS, prostate, breast cancer, etc., and in each
case the concentration required by the compound to exhibit
the activity was observed to be under 2 lM. All the screened
melanoma cancer cell lines were sensitive against the tested
compound and GI50 value was observed to be less than
1.56 lM. The maximum inhibition of growth of cell lines
was noted against the SNB-75 CNS cancer cell line (GI50 value
0.09 lM) and the least growth inhibitory activity against ovar-
ian cancer, NCI/ADR-RES ovarian cancer cell line (GI50 value
16.2 lM). The rest of all other subpanel cell lines exhibited
maximum sensitivity against the tested compound with not
more than 16.2 lM concentrations (Table 3). LC50 values for
the majority of the cell lines were greater than 100 lM with
exception to COLO 205 and DU-145, where LC50 was
observed to be very low (20.2 lM & 24.3 lM, respectively)
(Table 3). The log molar concentration (logGI50) values of
compound 4f against various cell lines ranged from 7.00 to
4.79. The minimum concentration (7.00) was observed
against CNS cancer subpanel of SNB-75 cell line, while for
NCI/ADR-RES cell line of ovarian cancer subpanel, logGI50
was the highest (4.79). The majority of the cell lines of sub-
panel showed logTGI and logLC50 values to be more than
>4.00 and except COLO 205 (colon cancer) and DU-145
(prostate cancer) cell lines for which logLC50 were noted to
be 4.69 and 4.61, respectively. Furthermore, a mean graph
midpoint (MG-MID) value of 4f was also calculated for
logGI50, logTGI and logLC50 parameters. MG-MID value is
the averaged activity parameter of GI50, TGI, or LC50 values
of all cell lines in the subpanel or the full panel toward thePlease cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dtested compound. The values were found on the lower side,
logGI50 (6.04), logTGI (4.38) and logLC50 (4.02) which
indicates efficacy of the screened compound (Table 4). The
selective index, which is a ratio of average sensitivity of all cell
lines to the average sensitivity of all cell lines of a particular
subpanel toward the tested compound, was also calculated to
measure the compound selectivity toward cell lines (Rostom,
2006). The selective index values between 3 and 6 indicate
moderate selectivity; ratios >6 is considered to have high
selectivity toward the corresponding cell line, while
compounds not meeting either of these criteria are referred
to as nonselective i.e. mild selectivity toward the corresponding
subpanel. Compound 4f, in the study exhibited moderate selec-
tivity toward prostate cancer cell lines with a selective index
3.66 and observed to be mild selective against breast cancer,
melanoma, leukemia and CNS cancer with a selective index
of 2.78, 2.71, 2.55 and 2.03, respectively (Table 3). A dose
response curve of synthetic compound 4f after exposure to var-
ious cancer cell lines in NCI60 panel was plotted between log10
of respective molar concentration of the sample versus percent-
age growth (PGs). The horizontal grid lines for comparison
purpose are drawn across the plot at percentage growth values
of +50, 0 and 50. The curved lines were coded with different
colors as per origin of tissues such as blue color for lung can-
cer; red color for leukemia cell line; the gray color for central
nervous system cancer; green color for colon cancer; purple
color for ovarian cancer; pink color for breast cancer cell line;
coral color for melanoma; golden color for renal cancer;
turquoise color for prostate cancer cell lines (Fig. 4). The plots
of percentage growth in cancer cell lines vs sample concentra-
tion at five different dose levels (1 log dilutions from
104 mol/L to 108 mol/L) after treatment with compound 4f
are shown in Fig. 5.
The dose response curve of compound 4f (NSC: 761982)
plotted for seven subpanels of colon cancer (Fig. 6), illustrates
the endpoint calculations for GI50, TGI and LC50 at five dose
concentrations. A value equal to ‘0’ growth percent suggests
no net growth or multiplication during the whole assay and
the number of cells at remain equals to quantity at time zero.
The calculated endpoints for the cell line COLO 205 of colon
subpanel (red open circle) were found as GI50 = 0.35,
TGI = 1.36 and LC50 = 20.2. All other cell lines of the colon
cancer subpanel such as HCC-2998 (red open diamond), HCT-
116 (red open triangle), HCT-15 (red open square), HT29
(solid blue circle), KM12 (solid blue diamond), and SW-620
(solid blue triangle) were found to be less sensitive than COLO
205 against the screened compound (Fig. 6). The in vitro anti-
cancer activity of compound 4f, the most potent and activezoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Figure 4 Dose response curves for all cell lines in the NCI 60 panel after exposed with compound 4f (NSC: 761982) of different
subpanels with originated colors and shapes.
18 M. Rashid et al.compound among the entire library of synthesized compounds
based on rational design was also compared with the biological
data obtained from the NCI web site for the clinically used
anticancer drugs (Bendamustine and Chlorambucil) in terms
of potency (lmol/L) by three response parameters and the
results are presented in Table 5. The tabulated results clearly
indicate that the compound 4f has lower mean values of log
molar concentration for response parameters viz. GI50 and
TGI50 and slightly higher mean value of LC50 as compared
to clinically used anticancer agents, bendamustine and
chlorambucil. Also, the mean graph midpoint GI50 value
(arithmetical mean value of treated cancer cell lines) of the
most potent compound 4f was observed to be only 2.09 lM,
which is much lower than the reference anticancer agents (60
and 52 lM, respectively) suggesting that the benzimidazole
endowed 1,3,4 oxadiazole compound holds promise as a
potential anticancer agent. It has been reported in the litera-
ture that benzimidazole derivatives act by inhibiting DNA
topoisomerase complex (Selcen et al., 2009; Singh and
Tandon, 2011) and their binding mode to DNA varies from
intercalation to groove binding based on the number of benz-
imidazole rings (Kubota et al., 1999). Therefore, there is a high
probability that antiproliferative effects of compound 4f, a
benzimidazole derivative which is attached to pyrimidine and
1,3,4 oxadiazole rings could be due to DNA intercalation.
However, the studies focusing on the mechanism of action of
these derivatives are currently under progress in our
laboratory.
3.3. Structural activity relationship (SAR)
On the basis of the obtained results, it can be concluded that,
benzimidazole analogues endowed with oxadiazole possess
excellent antiproliferative activities as compared to the other
benzimidazole clubbed thiadiazole, triazolo-thiadiazines and
triazolo-thiadiazoles derivatives. It was observed that the pres-
ence of electron withdrawing groups such as oxygen at ortho
(2nd position), meta (3rd position) or para (4th position)
position on aromatic ring of target compounds influences thePlease cite this article in press as: Rashid, M. et al., Design and synthesis of benzimid
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dantiproliferative activity. Compound 4g having free oxygen
group at ortho (2-one) position of phenyl ring, chemically as,
1-((5-(3-(1H-benzo [d] imidazol-2-yl)-3-oxopropyl)-1,3,4-oxa
diazol-2-yl)methyl)-4-amino pyrimidin-2(1H)-one, demon-
strated high sensitivity (78.75%) against NCI cancer cell lines
panel and likewise when the same group is disubstituted on
ortho and para (2,4-dione) positions of phenyl ring, an
augment in the sensitivity (20.03%) was observed for the
compound, 3-(5-(3-(1H-benzo [d] imidazol-2-yl)-3-oxopropyl)-
1,3,4-oxadiazol-2-yl)methyl)-5-methylpyrimidine-2,4(1H, 3H)-
dione (4f). Contrary to this, the electron donating groups such
as methoxy (AOCH3) attached at para (4th position) position
of the phenyl ring, a decrease in the sensitivity (93.97%) was
observed for compound 8b, namely, 1-(1H-benzo[d]imidazol-2-
yl)-3-(6-(4-methoxy phenyl)-7H-[1,2,4] triazolo [3,4-b] [1, 3]
thiazin-3-yl) propan-1-one. Similarly, the presence of methyl
group also decreased the sensitivity (94.39%) as observed for
the compound 5e, namely, 1-(1H-benzo[d]imidazol-2-yl)-3-(5-
(benzylthio)-1,3,4-thiadiazol-2-yl) propan-1-one. However, the
sensitivity of unsubstituted aromatic ring such as in compound
9a noted to be increased to (92.86%) in comparison with the
compounds bearing electron donating groups such as methoxy
and methyl as in compounds 8b and 5e.
3.4. Molecular docking studies
A number of research studies conducted elsewhere have
reported that benzimidazole derivatives act by inhibiting
DNA topoisomerase complex (Selcen et al., 2009; Singh and
Tandon, 2011). Therefore, the molecular interactions of the
compound 4f with the target protein, topoisomerase enzyme
complex were studied with the help of Maestro 9.0 molecular
docking software. The most fitting binding modes of com-
pound 4f in the active site of topoisomerase enzyme (1SC7)
are presented in Figs. 7 and 8.
Docking of the most active synthesized compound 4f into
the enzyme active site yielded a number of molecular interac-
tions showing hydrogen bond, p interaction and hydrophobic
interactions between the drug and enzyme and are consideredazoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Figure 5 Dose response curves at NCI fixed protocol, (lM) for all cell lines with different subpanels in the NCI 60 panel after treatment
with compound 4f (NCS: 761982/1). The curves of tested compound obtained from the NCI’s in vitro disease-oriented human tumor cells
line on nine cancer diseases at five concentrations (1 log dilutions from 104 mol/L to 108 mol/L). The tissue originated color and shapes
of NCI, subpanel cell lines indicative of growth percentage inhibition with concentration of tested sample.
Bendamustine analogues as new anticancer agents 19to be accountable for the noted affinity of the compound.
Though, compound 4f lacks Zwitter ion but it is able to form
hydrogen bonds with the enzyme through its secondary amino
group of benzimidazole/pyrimidine rings and carbonyl groupPlease cite this article in press as: Rashid, M. et al., Design and synthesis of benzimida
a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dwith the Arg 364 residue which is the same residue where the
natural inhibitor binds (Staker et al., 2005). In the hydrogen
bond interaction between the nitrogen (ANA) of the imidazole
ring of the compound 4f and the carboxyl group (C‚O) of thezoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Figure 6 Dose response curve of Colon cancer subpanel of
compound 4f (NSC: 761982) showing end point calculations for
COLO 205 cell line at five dose concentrations (1 log dilution from
104 mol/L to 108 mol/L).
Table 5 Comparison of in vitro anticancer activity between 4f and
Compd. NSCa no. Log (high conc.) Potency in log10(M) unit in
Unit GI50 EDP
d
(mean value)
T
(
4f 761982 4.79 log10(M) 6.04 
BENDAb 138783 4.0 log10(M) 4.153 
CHLBc 3088 5.0 log10(M) 4.758 
a National service center number.
b Bendamustine hydrochloride (Treanda).
c Chlorambucil (Leukeran).
d Endpoint.
e Number of cell lines.
f Mean graph midpoint (arithmetical mean value of treated cancer ce
Program, National Cancer Institute (NCI) main web site for comparison
Figure 7 Binding mode of compound 4f into the binding sites of to
(yellow dotted lines) with Arg 364 and pi interaction with Arg 364 an
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a source of new anticancer agents. Arabian Journal of Chemistry (2015), http://dx.dside chain residue of Arg 364 (1.73 A˚), the former acts as a
hydrogen bond donor while the later behaves as a hydrogen
bond acceptor. Further, in the second Hydrogen bond interac-
tion, the carbonyl group (C‚O) of the compound 4f acts as
the hydrogen bond acceptor and an amino group (NAH) of
the side chain residue of Arg 364 (2.39 A˚) is a hydrogen bond
donor (Fig. 7). The amide group of compound 4f seems to
have an important role in strong hydrogen bonding because
the lone pair electrons on nitrogen atom of the amide
delocalized into the carbonyl group of compound. Pi–p
interactions were also observed between the compound and
the binding site of enzyme, which are considered to play a
significant role in the inhibitory activity. As it can be seen in
the Lig plot (Fig. 8) of compound which shows the interactions
with binding site, it appears that oxadiazole and phenyl ring of
benzimidazole are properly oriented toward the more lipophi-
lic area of 1SC7 binding site and form CH-p interaction with
Arg 364 (4.83 A˚) and DNA pointed DG 12 (4.29 A˚) resides.
In addition to this, several hydrophobic interactions were also
observed between the phenyl ring, oxadiazole and pyrimidinemarketed anticancer drugs (bendamustine and chlorambucil).
lmol/L No. of expts N.C.L.e MIDf GI50
GI EDPd
mean value)
LC50 EDP
d
(mean value)
4.38 4.02 2 59 2.09
4.018 4.004 3 60 60
4.282 4.062 2 59 52
ll lines). Data were obtained from the Developmental Therapeutics
purpose.
poisomerase enzyme (PDB code: 1SC7) showing hydrogen bond
d DG 12.
azoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as
oi.org/10.1016/j.arabjc.2015.08.019
Figure 8 Lig plot of compound 4f showing interaction into the binding sites of topoisomerase enzyme (PDB code: 1SC7), hydrogen
bond (pink dotted line) with Arg 364 (1.73 A˚ and 2.39 A˚) and pi interaction (green solid line) with Arg 364 (4.83 A˚) and DG 12 (4.29 A˚).
Bendamustine analogues as new anticancer agents 21ring of compound 4f with the amino acid residues of the
enzyme topoisomerase including DA 14, DA 13, Tgp 11, Lys
532, Thr 718, Ile 535 and Asp 533 and shown in Figs. 7 and
8. The compound 4f was found to have a glide score value
of 5.39, indicating a high affinity and better interaction
between the compound and the enzyme.
4. Conclusion
A total of 22 novel heterocyclic compounds based on the
benzimidazole nucleus were prepared and characterized and
among them 15 molecules were chosen for studying their
anticipated antiproliferative activity against various human cell
lines by in vitro methods at NCI, USA. Notably, compound 4f
(3-(5-(3-(1H-benzo[d]imidazol-2-yl)-3-oxopropyl)-1,3,4-oxadia
zol-2-yl)methyl)-5-methylpyrimidine-2,4 (1H, 3H)-dione) was
identified as lead candidate exhibiting excellent antiproliferative
activity with MG-MID value GI50(2.09), log10GI50(6.04),
log10TGI(4.38) and log10LC50(4.02). The cytotoxic effects
of 4f molecule were at par with the marketed anticancer drugs,
chlorambucil and bendamustine. Furthermore, molecular
docking studies performedwith the help ofMaestro 9.0 software
program (Schrodinger Inc. USA) provided an insight into the
binding patterns of the compound 4f into the binding sites of
the DNA-topoisomerase complex. In view of these outcomes,
the further investigations on compound 4f may be carried in
search of potential new anticancer agents.
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